INTRODUCTION
Rubella was first described in English literature in 1815 by W. G. Maton, who pointed out the feature distinguishing it from scarlet fever and measles (rubeola). Rubella attracted little attention until 1941, when N. Gregg, an Australian ophthalmologist, noted that congenital defects occurred in babies whose mothers had experienced the disease early in pregnancy (Gregg, 1941) . This observation, subsequently confirmed and extended by many other investigators, stimulated a world-wide interest in preventing rubella.
The primary obstacle to the diagnosis and control of rubella was overcome in 1962 when two independent groups, Parkman, Buescher and Artenstein of the Walter Reed Army Medical Center (Parkman et al., 1962) and Weller and Neva of the Harvard School of Public Health (Weller and Neva, 1962 ), simultaneously described the isolation of rubella virus in tissue culture. Then, adequate serological methods became available for epidemiological survey. The surveys conducted in several countries revealed that in Europe and North America about 10-20% of women at the childbearing age are devoid of antibodies and thus exposed to the risk of infection during early pregnancy (Sever et al., 1964; Rawls et al., 1967) .
The demonstration of a high incidence of congenital anomalies following maternal infection, further evidenced during the 1963-64 epidemic in the United States, has stressed the urgent need for effective means of immunization against the disease in the United States and European countries (Cooper, 1971) .
The first successful attenuation of rubella virus was reported in 1966 (Parkman et al., 1966) . Thereafter, in the United States and Europe, several strains of attenuated rubella virus were licensed for vaccine production in 1969 (Parkman and Meyer, 1969; Huygelen et al., 1969) .
In Japan, an epidemic of rubella occurred in 1964-65 in Okinawa Islands, the southernmost part of Japan, and a high incidence of congenital rubella syndrome (CRS) that had never been experienced in this country was demonstrated by Ueda et al. (1967) . Thereafter, extensive outbreaks of rubella have been noticed among children and young adults in various parts of the main islands of Japan during the years from 1965 to 1969 (Shishido and Ohtawara, 1971) . Through this nation-wide epidemic, the total reported cases were roughly estimated at over 50,000. However, in comparison with such a large number of the reported cases, the incidence of CRS was extremely low; only less than 50 (Shishido and Ohtawara, 1971) * CM: Cardiac malformation , C: Cataract, D: Deafness ** Numbers in parentheses indicate serologically confirmed cases cases of CRS were reported during the time, as shown in Table I . For the reason of the low incidence of CRS in the main islands of Japan, presence of the antibody to rubella virus in majority of women at childbearing age was considered most likely. The possibility that the teratogenicity of the causative rubella virus differs from one epidemic to another was not excluded. The prevalence of rubella virus with lower teratogenic potentials than other strains in the main islands of Japan during these years was speculated (Kono, 1969) . Therefore, the development of rubella vaccine to prevent future epidemics was urgent in this country similarly as in the United States and other countries. In 1969, the Japan Rubella Vaccine Research Commission was organized with a number of investigators headed by one of the authors (A.S.), and the Commission undertook development of Japan-made rubella vaccines in co-operation with several laboratories for vaccine production in Japan. The study included a series of test preparations of live attenuated rubella vaccines, their laboratory tests, their clinical evaluations in field trials and follow-up study of vaccination. The laboratory tests were done mostly by one of us (M.O.) and the staffs of the Department of Measles Virus (Director, Dr. Shishido, A.), N.I.H., and clinical results were analyzed by Dr. Hirayama, M., Faculty of Medicine, Tokyo University, Dr. Kimura, M., School of Medicine, Tokai University, and the authors. The present review is to summarize the laboratory and clinical data of the study (Rubella Virus Vaccine Research Commission, 1971 , 1972 , 1973 Ohtawara et al., 1974) . PREPARATION 
OF VACCINES
A. Source of vaccine strain Parkman et al. (1966) firstly reported modification of a wild rubella virus strain by serial passages in primary green monkey kidney cells (GMK). The modified virus strain, obtained by 77 passages in GMK cultures and was designated as the High Passage Virus-77 (HPV-77) attenuated strain, was subsequently shown to be immunogenic, nonreactogenic and noncommunicable in children (Meyer et al., 1966) . Thereafter, the virus and its derivates were used to prepare a number of experimental live virus vaccines in several types of substrates such as GMK, primary dog kidney cultures (DK), and primary embryo cell cultures (CETC) (Parkman and Meyer, 1969) . Successful attenuation was achieved also by serial transfers of a wild rubella strain in duck embryo cell cultures (Hillerman, 1966; Stokes et al., 1966) , in WI-38 human diploid cells (Plotkin et al., 1966) and in primary rabbit kidney cells (Peetermans and Huygelen, 1967) .
At the beginning of our study, the source of the vaccine strain was discussed. At that time the Commission took an interest in the Kono's hypothesis that teratogenicity of Japanese rubella virus strains might be different from that of American strains. Kono proposed this hypothesis at first only from the epidemiological data of low incidence of congenital rubella in Japan (Kono, 1969) , but later from his own experiment of vertical transmission of rubella virus in rabbits . He suggested that rubella virus prevalent in 1966-69 in Japan seemed to be less virulent and less teratogenic than the isolates in the United States. Although his epidemiological explanation and experimental results still remain to be confirmed by other investigators, the Commission decided to use a strain of rubella virus prevalent in Japan for the vaccine strain. The decision may be feasible from the present status that no experiment to prove the safety of live vaccine for the fetus has been made or probably will ever be made (Shishido and Sato, 1974) .
B. Procedures for attenuation
Ten test preparations of live attenuated rubella vaccines were made in five laboratories by different procedures of attenuation. The strains for preparation of the vaccines are listed in Table II . The origins of the strains, their passage histories and procedures for attenuation have been described elsewhere in detail. They are summarized as follows.
1. ME-P vaccine: Okuno et al. (1968) succeded in isolating a strain (Matsuura strain) of rubella virus in primary African green monkey kidney (GMK) cells from a throat-swab specimen of a patient with rubella in Osaka district in 1966 and in adapting the virus to the amnion of the developing chick embryo. Experimental live attenuated rubella vaccines designated as ME6 and ME 11 were prepared for field trials from the infected amniotic materials of chick embryo (Minekawa et al., 1968) . Then the chick-embryo-adapted strain (ME) further passed in primary swine kidney (SK) cells were employed for preparation of another experimental vaccine (Suzuki et al., 1973) . In their own field trials they found that attenuation of the chick embryo-passaged strain was not complete, but progress of attenuation was seen during serial passages in SK cells.
The ME-P vaccine was prepared by Dr. Okuno along this line of study in co-operation with Kannonji Institute, the Research Foundation for Microbial Diseases of Osaka University.
2. MEQ7 and MEQ11 vaccines: Dr. Okuno made another attempt to attenuate the chick-embryo-adapted strain (ME) by passing it through primary Japanese quail embryo fibroblast cells (QEF). The Matsuura strain, after serial 65 passages in the amnion of chick embryo, was passaged serially in QEF. Two types of vaccines designated as MEQ7 and MEQ11 at different passages in QEF were prepared for field trials by Dr. Okuno in co-operation with Kannonji Institute, the Research Foundation for Microbial Diseases of Osaka University.
3. KRT vaccine: Ohwada et al. (the Kitasato Institute, Tokyo) developed KRT vaccine by serial passages of a wild rubella virus strain (Takahashi strain) in primary rabbit testicle (RT) cells (Nagashima, 1973; Ohwada et al., 1973; . The Takahashi strain (MAT) was isolated in GMK cells from a throat swab material of a rubella patient in Matsue city in 1968 (Itagaki et al., 1970 Matsuda et al. (1974) in GMK cells from a patient with rubella in Toyama prefecture in 1967. After seven passages in GMK cells, a passage series for attenuation was initiated in primary guinea pig kidney (GPK) cells. An experimental test vaccine was prepared in the laboratory from the virus at the 20th passage level in GPK cells (Oka et al., unpublished data) . As a substrate of the vaccine production, the primary rabbit kidney cell cultures were employed (Yaoi et al., unpublished data) .
5. SK vaccine: SK vaccine was developed in the Chemo-Sero-Therapeutic Research Institute, Kumamoto. The Matsuba strain isolated from a throat swab material of a patient with rubella in Kumamoto city served as the starting material. After three passages in GMK cells, a passage series for attenuation was initiated in primary SK cells. An experimental test vaccine was prepared in the institute from the virus at the 60th passage level in SK cells. As a substrate of the vaccine production, the primary rabbit kidney cell cultures were employed (Veda et al., 1974) .
6. TCRB19-1, TCRB19-2, TCRB21-1, and TCRB21-2 vaccines: The TCRB19 and TCRB21 strains were isolated from throat swab materials of patients with rubella in Tokyo in 1967 (Tabata, personal communication). After two passages in GMK cells, a passage series for attenuation was initiated in primary bovine kidney (BK) cell by Hashizume et al. in Chiba Serum Institute, Chiba. Four types of vaccine designated as TCRB19-l, TCRB19-2, TCRB21-1, and TCRB21-2 at different passages in BK cells were prepared for field trials by Dr. Hashizume.
C. Safety testing of experimental vaccine batches
All batches of experimental vaccines prepared for the present study in various laboratories mentioned above were checked for safety before clinical trials in each laboratory by general procedures outlined for live attenuated measles vaccine (Ministry of Health and Welfare, 1973) . The procedures included tests in tissue cultures, in eggs and in animals. For tests in tissue cultures , primary cells of human amnion, rabbit kidney, and chick embryo were employed; for those in animals, suckling and adult mice, guinea pigs, rabbits and monkeys were used. For tests in monkeys, intracerebral inoculation of vaccines was performed only to check the absence of any neurotropic agents in stead of confirmation of attenuation of virus, as wild rubella virus was shown to be completely devoid of neuropathogenicity to the monkey. All the vaccines employed in the present study were found approvable on these tests (Rubella Virus Vaccine Research Commission, 1971 , 1972 , 1973 Ohtawara et al., 1974) .
Potency measurement
In the early phase of laboratory studies on rubella virus , only GMK cell cultures were employed for measuring the virus infectivity . However, after various established cell lines such as Vero cells (Rhim and Schell , 1967) , SIRC cells (Rhim et al., 1967) , BHK-21 cells (Vaheri et al ., 1967) , and RK13 cells (Plotkin, 1965) were found susceptible to rubella virus, they were found to be useful also in quantitation of the virus . Subsequently, Hopps et al. (1969) As mentioned in the preceding chapter, all the vaccine viruses tested in this study grew well in RK13 and GMK cells. Parkman et al . (1967) reported first that an attenuated virus at a high passage level (HPV-77) had rapid and complete cytopathic effect in cultures of RK13 cells and also formed plaques in agar-overlaid monolayers of the cells, but virulent viruses at a low passage level failed to produce any significant change or plaques in the same cells . They suggested that such in vitro characteristics of the virus can be counted as one of markers of rubella virus for attenuation.
This marker characteristic was applied by many Japanese workers in their laboratories for checking the attenuation of rubella virus strains in passages in different cell cultures . The data are summarized in Table IV . Yaoi et al. (personal communication , 1970) found that the TO-336 strain of rubella virus produced distinct and large plaques in RK13 cells after passages in guinea pig kidney cells for attenuation . Okuno and his colleagues (Suzuki et al., 1973; Minekawa et al., 1973) Table V , regardless of the infection route, the hemagglutination-inhibition (HI) antibody to rubella virus was detected in all the animals in 2 or 3 weeks and reached the maximum titers in 4-5 weeks after infection. In a series of experiments it was found that a single injection of 0.5 log10 InD50 rubella virus was sufficient to evoke the HI antibody in the animals. Subsequently, we made an attempt to find if the Japanese vaccine strains had markedly reduced immunogenic properties in guinea pigs and rabbits. It was postulated that the reduced capacity to produce the antibody in experimental animals would be a useful in vivo marker for attenuation of vaccine strains.
1) Immunization schedules Hartley albino guinea pigs weighing approximately 350-400 g and New Zealand white rabbits weighing approximately 1.5-2.0 kg were used for immunization. All the animals were tested for the presence of rubella HI antibody at a serum dilution of 1:8 before they were included in the experiments. No rubella HI antibody was detected initially in any of the animals as reported by Oxford and Potter (1970) .
A single dose of 0.5 ml of the test vaccine was subcutaneously inoculated into each rabbit or guinea pig of a group of five. Six and 7 weeks after ino-OF ATTENUATED RUBELLA VIRUS VACCINES IN JAPAN 237
with M-33 and Takahashi strains of rubella virus culation, blood samples were taken for HI tests.
2) Immunogenicity of vaccine strains in rabbits. Rabbits were immunized with each of 10 strains. As controls, M-33 lowpassage laboratory strain and RA27 / 3 vaccine strain were employed. As shown in Table VI , four vaccine strains, MEQ11, TO-336, KRT and TCRB19-2, did not produce any detectable antibody in animals after inoculation of a single dose of 3.0-3.5 log10 InD50 of virus, while the remaining six Japanese vaccine strains, M-33 and RA27 / 3 strains, produced antibody to considerably high titers after immunization. HI titers of sera of individual animals immunized with vaccine strains including RA27 / 3 were variable, and generally much lower than those of animals immunized with M-33 strains.
3) Immunogenicity of vaccine strains in guinea pigs Guinea pigs were immunized similarly with each of 10 Japanese vaccine strains, RA27 / 3 and M-33 strains. As shown in Table VII , only three vaccine strains, MEQ7, TCRB19-1 and TCRB21-2, produced antibody; the other seven strains failed to produce any detectable antibody. Although the immunogenicity of the virus in guinea pigs seemed to be lost more easily than that in rabbits through passages in tissue cultures, the reduced immunogenicity might not be correlated with the animal species due to the different passage procedures em- 
4) Establishment of immunologic markers for Japanese vaccine strains
An important criterion for selection of markers of a virus vaccine is reproducibility in different laboratories. Our findings that some of the vaccine strains showed remarkably reduced capacities to produce antibody in guinea pigs as well as in rabbits were confirmed by other laboratories (Ohwada et al., 1973; Yaoi, personal communication; Minekawa et al., 1973 ; Hashizume, personal communication; Yoshikawa, personal communication). Another important criterion is stability of the marker properties. In clinical studies on test vaccines, we attempted to characterize the immunological marker of several strains reisolated from the vaccinees receiving experimentally these vaccines. The results will be described in detail in the following chapter dealing with clinical evaluation. As will be described, no reversion of marker properties was detected, accordingly the immunologic marker for Japanese vaccine strains was established. Trials were carried out mostly in orphanages and other institutions. In this study, 20-40 children in one institution were devided into two groups; one was vaccinated subcutaneously and the other served as contact controls. Clinical signs, particularly skin rash, fever, and lymphadenopathy, were carefully observed by physicians and nurses of the institutions for 3 weeks after injection. Blood specimens for the HI-antibody titration were taken at vaccination and 6 weeks and 8 weeks later from the vaccinees and the contact controls, respectively. Isolation of vaccine virus from vaccinees was attempted with the throat washings on 7, 10, 14, 17 and 21 days of injection. OF The results obtained with vaccinees of 10 different vaccines are summarized in Table VIII . About 60-170 susceptible children in five or more institutions were injected with each vaccine. Contact controls of nearly the same number were kept for evidence of virus spread from vaccinees. As shown in the table, a few vaccinees except an ME-P vaccine recipient experienced mild symptom attributable to the attenuated virus inoculation. The serological response was satisfactorily high with all the vaccinees. In almost all the vaccines, the seroconversion rate was higher than 95%, and the geometric mean of antibody titers in the serologically converted children ranged from 26.3 to 27.6 with ME-P, MEQ7, TO-336, KRT, SK, TCRB19-1 and TCRB19-2 and was somewhat lower with MEQ11 (25.7).
The incidences of fever, rash and lymphadenopathy among ME-P vaccinees were calculated to be 30.1%, 10.8% and 19.3%, respectively, indicating that the vaccine virus had not been attenuated enough for general use in children. From this reason, ME-P vaccine was excluded from the field trials of the second step . Tables VIII and IX. and at the same time non-vaccinated rubella-susceptibel children were kept in close contact with the vaccinees for a period of 8 weeks after vaccination. As shown in Table VIII , rubella virus was recovered from vaccinees at rates of 2.7% to 71.5% between days 7 and 21 after vaccination. Nevertheless none of the contact children except those exposed to M-P and MEQ7 developed rubella antibodies, which confirmed the non-communicability of these vaccine strains. With ME-P vaccine, five of 71 contacts (7.0%) showed clinical symptoms, and 14 (19.7%) developed the antibody, while only two among 91 contacts with MEQ7 vaccine developed the antibody without any clinical symptom. This indicates that both vaccine strains still maintained communicability, although the former was more communicable than the latter. These results coincide with the clinical findings of marked reactions with ME-P vaccine in contrast to no reaction with MEQ7. With MEQ7 vaccine, it was carefully studies to see if any serologic conversion occurs among the control contact group with wild rubella virus instead of vaccination during the observation period, but any possible invasion of the virus from the outside was not proven. Accordingly, after due discussion, the Commission decided to stop using the MEQ7 vaccine for further trials. Trials were carried out on children at ages of 1 to 14 years in kindergarten, primary school, or junior high school. The inquiry cards were distributed to the parents of the vaccinated children to know the incidence of untoward effects. Trials were carried out also on young adult women, mostly high-school girls and nursing-school students at ages of 15-21 years. The inquiry cards were distributed also to the vaccinees themselves to confirm the incidence of untoward effects. Isolation of vaccine virus was attempted from vaccinees of only a limited number.
Clinical reactions, antibody responses, and virus spread from vaccinees
In the open study, safety and effectiveness of the vaccines were investigated in large groups of vaccinees by observing clinical reactions and antibody responses as in the cases of closed studies. Over 500 individuals including both children and young adult women were injected with each of test vaccines. In these trials, differences in clinical reactions between children and young adults were carefully investigated in each vaccinated group. Since clinical reaction of natural rubella in children generally tends to be milder than that in adults (Krugman, 1965; Brody et al., 1965) , such differences in clinical reaction by ages were predicted from vaccination.
In early trials of the open studies, one of the test vaccine, TCRB21-2, slightly modified TCRB21-1 vaccine that was considered to be approvable in closed studies, was found to produce rather severe clinical reactions in young adults as compared with children. As shown in Table IX , 83 children administered with TCRB21-2 vaccine in open studies showed few clinical reaction as those administered with TCRB21-1 or TCRB19-1 in the closed studies, but 37 young adult women administered with the same vaccine often showed such definite clinical reactions as fever, rash, lymph adenopathy and arthritis or arthragia in 5 (13.5%), 24 (64.9%), 22 (59.5%) and 16 (43.2%) vaccinees, respectively. In contrast, among 207 young adults and 377 children vaccinated with TO-336 vaccine, only a few individuals showed mild clinical reactions, although the incidence of clinical reactions among young adults was somewhat higher than children. As the results, TO-336 vaccine was admitted to open studies with children and young adult women, but TCRB11-2 was rejected because of its severe reactivity in the older age group. to more than 500 individuals, both children and young adults, and MEQ11 to fewer individuals. Slightly more clinical reactions were recorded in open studies than in closed ones as mentioned above, but no apparent difference between children and young adults was noticed. As to seroconversion, at least 97% of the susceptible child and young adult recipients of each vaccine responded with development of the HI antibody. The geometric means of antibody titers in each vaccine group ranged from 25.2 to 27.1 in children and from 24.7 to 26.1 in young adults, the reactivity being slightly higher in the former than the latter. As indicated in closed studies on children, rubella virus was recovered rather frequently from vaccinees except those receiving MEQ11 vaccine. However, spread of the virus from such vaccinees to susceptible individuals was not noticed. For safety of vaccination, it is important to prove that no reversion of marker properties of vaccine strains would ever occur even after passages in man (Linnemann et al., 1974) . For this purpose, four re-isolates from the recipients of each of three vaccines, TO-336, KRT and TCRB19-2, in the closed study were selected, and 100.4-103.6 InD50 of each virus were inoculated into 6/8 guinea pigs for the in vivo marker test (see chapter 3). OF ATTENUATED RUBELLA VIRUS VACCINES IN JAPAN 247 A principal basis for assessing the value of any vaccine is the durability of the protective immunity after vaccination. On the persistence of the circulating antibody to rubella in vaccinees after immunization with live attenuated rubella vaccines, a number of studies have been conducted in the United States mostly with licensed vaccines. Meyer and Parkman (1971) , in a 7-year follow-up of institutionalized children, observed a pattern of antibody persistence after administration of HPV-77 DE-5 vaccine similar to that natural infection , though of lower magnitude. Similar findings have been reported by Farquhar (1972 Farquhar ( , 1973 i n 3 and 4 years' follow-up studies of Cendehill vaccine . Black et al. (1976) recently pointed out that re-infection of natural rubella after vaccination with live-attenuated rubella vaccine might elicit booster response during such a long-term follow-up study , and they attempted to measure the antibody in virgin-soil population of Amazon Indian immunized with RA27/3 vaccine. Consequently, the level of HI antibody titers to rubella virus 2 years after vaccination was found not to be appreciably lower than that of naturally derived antibodies after 4 to 12 years .
After the clinical evaluation, Japanese candidate live-attenuated rubella vaccines have also examined for the durability of immunity . and Horiuchi et al . (1974) observed independently in groups of school children and young adult women that all the vaccinees retained antibody 1, 11 and 2 years after administration of KRT vaccine . also observed in 153 vaccinees including institutionalized children and nursing-school students persistence of antibody at least for 12 months after vaccination with SK vaccine.
Besides these studies, the Commission started in 1972 to follow the persistence of immunity against natural rubella infection in more than 500 children vaccinated with either TO-336, KRT, SK , TCRB19-2 or MEQ11 vaccine. The follow-up study was designed according to similar studies performed on measles vaccine (Shishido et al., 1973) ; thus survellance for persistence of the antibody in the vaccinees and evaluation of the protective immunity against natural rubella infection were included. By the members of the Commission who participated in the clinical studies mentioned above, the study is now in progress . It has been proven that the vaccinees retain the HI antibody to rubella virus for at least 2 years and are protected against rubella infection for 3 years after vaccination (Sugishita et al., 1975; Shishido et al ., 1976 On a clinical basis, the requirements for a live attenuated rubella virus vaccine are threefold: immunogenicity, non-communicability and non-reactogenicity. All the data accumulated in the studies of clinical evaluation conducted mainly by the Commission in Japan indicatd that five candidate vaccines, TO-336, SK, KRT, MEQ11 and TCRB19-2 vaccines, seemed to meet the requirements for safe and effective live attenuated rubella vaccine (Table X) . However, on the virological basis, the established marker characteristics, either in vitro or in vivo, of the virus is most desirable for the vaccine strain for the acceptability in general use.
Since wild rubella virus causes congenital deformity, it is possible at least theoretically that live attenuated rubella viruses can do the same, although it seems difficult so far to asses the actual teratogenic potential of live virus vaccine (Wyll and Herrmann, 1973; Modin et al., 1976) . Therefore, rubella vaccination is contraindicated for 2 months before and at any time during pregnancy (U.S. Public Health Service Advisory Committee, 1971). In this sense, it would be necessary for us to provide means to answer the questions related to the administration of vaccines, such as the possible occurrence of induced abortion, deformity of the infants, and other suffering among individuals who are inadvertenly vaccinated or closely contacted with the vaccinees during pregnancy.
Immunogenicity
in guinea pigs and rabbits of the virus was proven to be a useful marker at least to distinguish wild and vaccine viruses when necessary, although the significance as an attenuation marker is still not very clear.
After due discussion on five candidate vaccines, the Commission and the Advisory Committee of Standardization of Rubella Vaccine recommended to approve four live, attenuated rubella virus vaccine, TO-336, KRT, MEQ11 and TCRB19-2, for general use in Japan, as these vaccines were found to meet the requirements both on the clinical and virological bases. Another candidate, SK vaccine, was rejected because of insufficiency in the immunogenicity marker. According to this recommendation, the four vaccines were licensed in the autumn of 1975 by the authority of Ministry of Health and Welfare of the Japanese Government. Since then the vaccination program of rubella vaccine in Japan has been put in action.
In the United States, licensing the vaccine in 1969 , an attempt has been made to control the disease by a large-scale immunization mostly on infants and children. The initial results of this policy seemed to be successful (Krugman and Katz, 1974) . On the basis of the recent report (Center for Disease Control , 1976) , it can be said that a steady decline in incidence and a downward trend of CRS have clearly been demonstrated since the immunization started in 1969 , and being more important, it was found that the wide-scale epidemic predicted for the early 1970s has not materialized in that country .
In the United Kingdom and some other European countries, the rubella vaccine policy has been the delay of immunization until about 12 years of ages (Dudgeon, 1970) . This allows natural infection to immunize over 50% girls before the age, and tops up immunity before the childbearing years . It seems important to try to immunize girls before the birth of their first children , because, for example, the surveillance made in England and Wales for congenital malformation due to rubella shows that 48% occur in the first births (Dudgeon et al., 1973) .
Following the licensing of live attenuate rubella vaccine in 1975 , the immunization program of rubella vaccine in Japan has been discussed in Advisory Committee on Immunization practices (Chairman: Dr. S . Someya) by consulting Subcommittee of Rubella Vaccine (Chairman: Dr. A. Shishido) . From the epidemiologic situation on rubella in Japan, it was recommended at present that in this country the immunization is to be concentrated on girls at 12-14 years . 
